Asymmetric dimethylarginine, NO and collateral growth

Anadolu Kardiyoloji Dergisi

Volumn 9, Issue 5, 2009, Pages 417-420

  Kocaman, Sinan Altan ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

ADMA; Atherosclerosis; Collateral; Endothelial dysfunction; Nitric oxide

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; TYROSINE KINASE RECEPTOR; VASCULOTROPIN;

ADAPTATION; ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; BLOOD VESSEL TONE; CELL REGENERATION; COLLATERAL CIRCULATION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE DURATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME ACTIVE SITE; ENZYME RELEASE; ENZYME SYNTHESIS; GROWTH RATE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; REVIEW; RISK FACTOR; UPREGULATION;

ARGININE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; HUMANS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RISK FACTORS;

EID: 70849137364     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Billinger M, Kloos P, Eberli FR, Windecker S, Meier B, Seiler C. Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow up study in 403 patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 1545-1550 (Pubitemid 35253630)
2. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, et al. Influence of coronary collateral vessels on myocardial infarct size in humans: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial. The TIMI investigators. Circulation 1991; 83: 739-746
3. Hansen JF. Coronary collateral circulation: clinical significance and influence on survival in patients with coronary artery occlusion. Am Heart J 1989; 117: 290-295
4. Maseri A, Araujo L, Finocchiaro ML. Collateral development and function in man. In: Schaper W, Schaper J, editors. Collateral circulation: heart, brain, kidney, limbs. Boston MA; Kluwer Academic Publishers: 199. P. 381-402.
5. Tayebjee MH, Lip GY, MacFadyen RJ. Collateralization and the response to obstruction of epicardial coronary arteries. QJM 2004; 97: 259-272
6. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012
7. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
8. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-523 (Pubitemid 41040296)
9. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-992 (Pubitemid 34925335)
10. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847.
11. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetric dimethylarginine. Lancet 2001; 358: 2127-2128 (Pubitemid 34094905)
12. Şahinarslan A, Çengel A, Biberoǧlu G, Hasanoǧlu A, Türkoǧlu S, Timurkaynak T. Plasma asymmetric dimethylarginine level and extent of lesion at coronary angiography. Coron Artery Dis 2006; 17: 605-609
13. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152: 493. e1-8.
14. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97: 53-59
15. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, et al. Asymmetric dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007; 53: 273-283 (Pubitemid 46338272)
16. Kornowsky R. Collateral formation and clinical variables in obstructive coronary artery disease: the influence of hypercholesterolemia and diabetes mellitus. Coron Artery Dis 2003; 14: 61-64
17. Kilian JG, Keech A, Adams MR, Celermajer DS. Coronary collateralisation: determinants of adequate distal vessel filling after arterial occlusion. Coron Artery Dis 2002; 13: 155-159 (Pubitemid 34747963)
18. Pohl T, Seiler C, Billinger M, Herren E, Wustmann K, Mehta H, et al. Frequency distribution of collateral flow and factors influencing collateral channel development. J Am Coll Cardiol 2001; 38: 1872-1878
19. Abaci A, Oǧuzhan A, Kahraman S, Eryol NK, Ünal S, Arinç H, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999; 99: 2239-2242 (Pubitemid 29201128)
20. Sherman JA, Hall A, Malenka DJ, De Muinck ED, Simons M. Humoral and cellular factors responsible for coronary collateral formation. Am J Cardiol 2006; 98: 1194-1197 (Pubitemid 44584100)
21. Sellke FW, Wang SY, Stamler A, Lopez JJ, Li J, Simons M. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol 1996; 271: 713-720
22. Metais C, Li J, Simons M, Sellke FW. Effects of coronary artery disease on expression and microvascular response to VEGF. Am J Physiol 1998; 275: 1411-1418
23. Matsunaga T, Warltier DC, Weihrauch DW, Moniz M, Tessmer J, Chilian WM. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 2000; 102: 3098-3103
24. Kocaman SA, Şahinarslan A, Biberoǧlu G, Hasanoǧlu A, Akyel A, Timurkaynak T, et al. Asymmetric Dimethylarginine and Coronary Collateral Vessel Development. Coron Artery Dis 2008; 19: 469-474
25. Van Belle E, Rivard A, Chen D, Silver M, Bunting S, Ferrara N, et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997; 96: 2667-2674 (Pubitemid 27451360)
26. Turhan H, Yaşar AS, Erbay AR, Yetkin E, Şaşmaz H, Sabah I. Impaired coronary collateral vessel development in patients with metabolic syndrome. Coron Art Dis 2005; 16: 281-285 (Pubitemid 41073296)
27. Yilmaz MB, Biyikoǧlu SF, Akin Y, Güray U, Kisacik HL, Korkmaz S. Obesity is associated with impaired coronary collateral vessel development. Int J of Obesity 2003; 27: 1541-1545 (Pubitemid 38019169)
28. Amano K, Matsubara H, Iba O, Okigaki M, Fujiyama S, Imada T, et al. Enhancement of ischemia-induced angiogenesis by eNOS overexpression. Hypertension 2003; 41: 156-162 (Pubitemid 36056808)
29. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-2578 (Pubitemid 28270451)
30. Unthank JL, Nixon JC, Dalsing MC. Nitric oxide maintains dilation of immature and mature collaterals in rat hindlimb. J Vasc Res 1996; 33: 471-479
31. Güleç S, Karabulut H, Özdemir AO, Özdöl C, Turhan S, Altin T, et al. Glu298Asp polymorphism of the eNOS gene is associated with coronary collateral development. Atherosclerosis 2008; 198: 354-359 (Pubitemid 351707386)
32. Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B, et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005; 111: 1431-1438 (Pubitemid 40396810)
33. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of reninangiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24: 1682-1688 (Pubitemid 39180895)